rs1554097246
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PVS1PP5_Moderate
The ENST00000253496.4(F12):c.971_1018+24del variant causes a splice donor, splice donor 5th base, coding sequence, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000837 in 1,434,486 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Genomes: not found (cov: 0)
Exomes 𝑓: 0.0000084 ( 0 hom. )
Consequence
F12
ENST00000253496.4 splice_donor, splice_donor_5th_base, coding_sequence, intron
ENST00000253496.4 splice_donor, splice_donor_5th_base, coding_sequence, intron
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.153
Genes affected
F12 (HGNC:3530): (coagulation factor XII) This gene encodes coagulation factor XII which circulates in blood as a zymogen. This single chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged. [provided by RefSeq, Jul 2008]
GRK6 (HGNC:4545): (G protein-coupled receptor kinase 6) This gene encodes a member of the guanine nucleotide-binding protein (G protein)-coupled receptor kinase subfamily of the Ser/Thr protein kinase family. The protein phosphorylates the activated forms of G protein-coupled receptors thus initiating their deactivation. Several transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, LoF is a know mechanism of disease, No cryptic splice site detected. Exon removal results in frameshift change.
PP5
Variant 5-177404171-CTCCTTCCCCCCCCCACTTCCTAACCTCCCGGGGTCTGGGACTGAGGCGGGGTCCGGGTCGTGGGCTGAGGCT-C is Pathogenic according to our data. Variant chr5-177404171-CTCCTTCCCCCCCCCACTTCCTAACCTCCCGGGGTCTGGGACTGAGGCGGGGTCCGGGTCGTGGGCTGAGGCT-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 441533.Status of the report is criteria_provided_single_submitter, 1 stars. Variant chr5-177404171-CTCCTTCCCCCCCCCACTTCCTAACCTCCCGGGGTCTGGGACTGAGGCGGGGTCCGGGTCGTGGGCTGAGGCT-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
F12 | NM_000505.4 | c.971_1018+24del | splice_donor_variant, splice_donor_5th_base_variant, coding_sequence_variant, intron_variant | 9/14 | ENST00000253496.4 | NP_000496.2 | ||
F12 | XM_011534462.3 | c.635_682+24del | splice_donor_variant, splice_donor_5th_base_variant, coding_sequence_variant, intron_variant | 6/11 | XP_011532764.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
F12 | ENST00000253496.4 | c.971_1018+24del | splice_donor_variant, splice_donor_5th_base_variant, coding_sequence_variant, intron_variant | 9/14 | 1 | NM_000505.4 | ENSP00000253496 | P1 |
Frequencies
GnomAD3 genomes Cov.: 0
GnomAD3 genomes
Cov.:
0
GnomAD3 exomes AF: 0.0000150 AC: 2AN: 133604Hom.: 0 AF XY: 0.0000276 AC XY: 2AN XY: 72350
GnomAD3 exomes
AF:
AC:
2
AN:
133604
Hom.:
AF XY:
AC XY:
2
AN XY:
72350
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000837 AC: 12AN: 1434486Hom.: 0 AF XY: 0.0000127 AC XY: 9AN XY: 711312
GnomAD4 exome
AF:
AC:
12
AN:
1434486
Hom.:
AF XY:
AC XY:
9
AN XY:
711312
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 0
GnomAD4 genome
Cov.:
0
Alfa
AF:
Hom.:
ClinVar
Significance: Likely pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Hereditary angioedema type 3 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | Nöthen Lab, Institute of Human Genetics, University Hospital Bonn | - | Reported in two families with hereditary angioedema type III, Family I: observed in two affected females and one unaffected male. Family II: observed in two affected females and one unaffected male and one unaffected female (Bork et al. 2011 PMID: 21849258 and Bork et al. 2014 PMID: 25113305) A reduced penetrance for males is well known, it is estimated at <10%. Functional consequences have been demonstrated experimentally (de Maat et al. 2016 PMID: 27130860). - |
Likely pathogenic, criteria provided, single submitter | clinical testing | ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology | - | - - |
F12-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 13, 2024 | The F12 c.971_1018+24del72 variant is predicted to result in an in-frame deletion (p.Lys324_Ala340delinsThr). This variant in the heterozygous condition was reported in 4 affected individuals and 3 unaffected individuals from two unrelated Turkish families with hereditary angioedema and normal C1 inhibitor (Bork et al. 2011. PubMed ID: 21849258; Bork et al. 2014. PubMed ID: 25113305). This variant was also reported in one individual with ACE inhibitor-induced angioedema (Veronez et al 2017. PubMed ID: 28483295). Functional studies suggest that this variant affects protein normal function (de Maat S et al 2016. PubMed ID: 27130860). It is reported in 0.0043% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as likely pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at